580696.fig.005a
(a)
580696.fig.005b
(b)
580696.fig.005c
(c)
Figure 5: Treatment with the EV71-specific antibody from infected CD4−/− mice reduces the lethality and disease severity of infected B−/− mice by decreasing tissue viral loads. The (a) survival rates and (b) disease scores of infected B−/− mice given the control antibody (control Ab; ) from noninfected CD4−/− mice or the EV71-specific antibody (EV71 Ab; ) from infected CD4−/− mice are shown. (c) The viral titers in the indicated tissues of B−/− mice given control antibody (control Ab; ) or EV71-specific (EV71 Ab; ) antibody 5 days after infection are shown. The data shown in (b) and (c) are the mean values ± or plus SE values (error bars). Survival rates that are significantly different ( ) by the log-rank test are indicated ( ). Disease scores that are significantly different ( ) by the Wilcoxon signed-rank test are indicated ( ). Viral titers that are significantly different ( ) by the Mann-Whitney U test are indicated ( ).